Haemato-Biochemical Changes and Therapeutic Outcomes in Cerebral Babesiosis in Dogs
DOI:
https://doi.org/10.48165/ijvsbt.2026.22.06.10Keywords:
Babesia gibsoni, Cerebral babesiosis, Dogs, Haematology, Neurological signs, Serum biochemistryAbstract
Canine cerebral babesiosis is a rare, but life threatening neurological manifestation of Babesia gibsoni infection with scant documentation in India. The aim of the present study was to evaluate the clinical, haemato-biochemical changes with response to treatment in dogs with cerebral babesiosis (n=11). Cerebral babesiosis was initially suspected based on the presence of characteristic neurological signs and subsequently confirmed by microscopic examination of stained peripheral blood smears, and molecular confirmation by species-specific PCR targeting the 18S rRNA gene of Babesia gibsoni, which yielded the expected 670-bp amplicon. Eleven dogs diagnosed with cerebral babesiosis were treated with diminazene aceturate, doxycycline, enrofloxacin, metronidazole, and supportive medications. Clinical, haematological and serum biochemical parameters were assessed on days 0, 3, 7, 14 and 28 post-treatment. Neurological signs included ataxia, hind limb stiffness, paddling, opisthotonus, seizures, head pressing, stupor, circling, nystagmus, blindness and paraplegia, which mostly improved slowly after treatment. Haematological evaluation showed anaemia, leukocytosis and marked changes in the lymphocyte, eosinophil and monocyte profiles in the early phase. Haemoglobin and erythrocyte parameters improved progressively after therapy and leukocyte abnormalities progressively approached the values recorded in apparently healthy dogs. Serum biochemical analysis showed significant changes in albumin, ALT, ALP, total bilirubin, direct bilirubin and BUN. High concentrations of ALT, ALP, bilirubin and BUN were observed at the beginning of the study and gradually decreased with treatment, while albumin concentration increased in the direction of the normal range. There were no significant differences in globulin, A/G ratio, creatinine, indirect bilirubin, glucose and magnesium. Results suggest cerebral babesiosis is associated with a poor prognosis despite intensive therapy, and combination chemotherapy with appropriate supportive care improved clinico-pathological and haemato-biochemical parameters and recovery of surviving dogs. Early diagnosis and treatment are thus still important to improve clinical outcomes.
Downloads
References
Adaszek, L., Górna, M., Klimiuk, P., Kalinowski, M., & Winiarczyk, S. (2012). A presumptive case of cerebral babesiosis in a dog in Poland caused by a virulent Babesia canis strain. Tierärztliche Praxis Ausgabe K: Kleintiere Heimtiere, 40(5), 367–371.
An, H. M., Song, J. H., An, S. J., Yu, D., Han, D., Kim, Y. J., & Jung, D. I. (2019). Clindamycin-doxycycline-metronidazole combination therapy in a refractory canine babesiosis case. Journal of Biomedical and Translational Research, 20(3), 71–74.
Baneth, G. (2018). Antiprotozoal treatment of canine babesiosis. Veterinary Parasitology, 254, 58–63.
Bilwal, A. K., Mandali, G. C., & Tandel, F. B. (2017). Clinicopathological alterations in naturally occurring Babesia gibsoni infection in dogs of Middle-South Gujarat, India. Veterinary World, 10(10), 1227–1232.
Birkenheuer, A. J., Levy, M. G., & Breitschwerdt, E. B. (2004). Efficacy of combined atovaquone and azithromycin for therapy of chronic Babesia gibsoni (Asian genotype) infections in dogs. Journal of Veterinary Internal Medicine, 19(4), 494–498.
Chan, K., Bęczkowski, P. M., & Almendros, A. (2025). Clinical and clinicopathological features of 108 dogs infected with Babesia gibsoni in Hong Kong. Animals, 15(5), 645.
Gonde, S., Chhabra, S., Uppal, S. K., Singla, L. D., & Randhawa, S. S. (2016). A unique case of Babesia gibsoni infected dog with paraplegia. Journal of Parasitic Diseases, 40, 1605–1608.
Lin, E. C., Chueh, L. L., Lin, C. N., Hsieh, L. E., & Su, B. L. (2012). The therapeutic efficacy of two antibabesial strategies against Babesia gibsoni. Veterinary Parasitology, 186, 159–164.
Malinovska, Z. (2024). Canine babesiosis and therapy options: A review. Folia Veterinaria, 68(2), 49–56.
Reddy, B. S., Sivajothi, S., & Swetha, K. (2022). Intravenous clindamycin as a monotherapy in treatment of Babesia gibsoni in dogs. Chemical Science Review and Letters, 11(44), 475–477.
Reddy, B. S., Sivajothi, S., Reddy, L. S. S., & Raju, K. G. S. (2014). Clinical and laboratory findings of Babesia infection in dogs. Journal of Parasitic Diseases, 38(3), 268–272.
Reddy, S. T. C., Chandrashekhariah, A. K. M., Appaiah, K. M., Murag, S., Kumar, K. R. A., & Hanumantha, P. B. (2024). Haemato-biochemical changes in dogs affected with immune mediated haemolytic anaemia caused by Babesia gibsoni. Indian Journal of Veterinary Sciences and Biotechnology, 20(4), 105–109.
Sai, P. S. K., Vijayalakshmi, P., Abiramy, P. A., Devadevi, N., Rajkumar, K., & Ratnam, D. H. S. S. (2023). Clinical, haemato-biochemical evaluation and comparison of polymerase chain reaction with conventional blood smear examination for the detection of Babesia gibsoni infection in dogs. Indian Journal of Veterinary Sciences and Biotechnology, 19(5), 33–36.
Sivajothi, S., & Reddy, B. S. (2017). Successful management of nervous signs due to babesiosis in a dog. International Journal of Veterinary Sciences and Animal Husbandry, 2(3), 33–34.
Sivajothi, S., Reddy, B. S., & Swetha, K. (2023). Cerebrospinal fluid analysis and haemato-biochemical variations in young buffalo calves with cerebral babesiosis. Journal of Parasitic Diseases, 47(4), 815–819.
Thakur, D. S. S., Changkija, B., Barman, U., Das, A., Nath, M. K., Lahkar, D., & Barman, N. N. (2024). Renal azotemia and associated haematobiochemical findings in a Labrador Retriever dog with Babesia gibsoni infection. International Journal of Advanced Biochemistry Research, SP-8(10), 666–670.
Published
Issue
Section
License
Copyright (c) 2026 Indian Journal of Veterinary Sciences and Biotechnology

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

